MX9401807A - Usos terapeuticos de productos de proteina que incrementan lapermeabilidad/bactericidas. - Google Patents
Usos terapeuticos de productos de proteina que incrementan lapermeabilidad/bactericidas.Info
- Publication number
- MX9401807A MX9401807A MX9401807A MX9401807A MX9401807A MX 9401807 A MX9401807 A MX 9401807A MX 9401807 A MX9401807 A MX 9401807A MX 9401807 A MX9401807 A MX 9401807A MX 9401807 A MX9401807 A MX 9401807A
- Authority
- MX
- Mexico
- Prior art keywords
- protein products
- bactericides
- therapeutic uses
- increase permeability
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
La presente invención proporciona métodos terapéuticos para el tratamientode condiciones que incluyen la neutralización de la actividadanticoagulante de la heparina, inhibición de la angiogénesis, de laproliferación celular endotelial y tumoral, así como el tratamiento deenfermedades inflamatorias crónicas mediante la administración deproductos de proteína que incrementan la permeabilidad/bactericidas (BPI).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/030,644 US5348942A (en) | 1993-03-12 | 1993-03-12 | Therapeutic uses of bactericidal/permeability increasing protein products |
US9320293A | 1993-07-15 | 1993-07-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9401807A true MX9401807A (es) | 1995-01-31 |
Family
ID=26706282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9401807A MX9401807A (es) | 1993-03-12 | 1994-03-11 | Usos terapeuticos de productos de proteina que incrementan lapermeabilidad/bactericidas. |
Country Status (16)
Country | Link |
---|---|
US (3) | US5639727A (es) |
EP (2) | EP0690720B1 (es) |
JP (3) | JPH08509703A (es) |
CN (2) | CN1105574C (es) |
AT (1) | ATE202482T1 (es) |
AU (1) | AU684503B2 (es) |
CA (1) | CA2157927C (es) |
DE (1) | DE69427582T2 (es) |
DK (1) | DK0690720T3 (es) |
ES (1) | ES2157981T3 (es) |
GR (1) | GR3036686T3 (es) |
HK (1) | HK1014497A1 (es) |
MX (1) | MX9401807A (es) |
NZ (1) | NZ263057A (es) |
PT (1) | PT690720E (es) |
WO (1) | WO1994020128A1 (es) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5198541A (en) * | 1987-08-11 | 1993-03-30 | New York University | Dna encoding bactericidal/permeability-increasing proteins |
US5420019A (en) * | 1993-02-02 | 1995-05-30 | Xoma Corporation | Stable bactericidal/permeability-increasing protein muteins |
US5652332A (en) * | 1993-03-12 | 1997-07-29 | Xoma | Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof |
US6214789B1 (en) | 1993-03-12 | 2001-04-10 | Xoma Corporation | Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products |
DK0690720T3 (da) * | 1993-03-12 | 2001-08-27 | Xoma Technology Ltd | Terapeutiske anvendelser af baktericide/permeabilitetsforøgende proteinprodukter |
WO1995000641A1 (en) | 1993-06-17 | 1995-01-05 | Xoma Corporation | Lipopolysaccharide binding protein derivatives |
US5770561A (en) * | 1993-07-14 | 1998-06-23 | Xoma Corporation | Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products |
AU7330994A (en) * | 1993-07-14 | 1995-02-13 | Xoma Corporation | Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products |
CN1133634A (zh) * | 1993-09-22 | 1996-10-16 | 爱克斯欧玛公司 | 定量体液中的bpi的方法 |
ES2178656T3 (es) * | 1993-09-22 | 2003-01-01 | Xoma Technology Ltd | Metodo para tratar infeccion bacteriana gram-negativa por administracion de productos de proteina bactericida que aumenta la permebilidad(bpi) y antibioticos. |
US6759203B1 (en) | 1993-09-22 | 2004-07-06 | Xoma Corporation | Method for quantifying BPI in body fluids |
PT754050E (pt) * | 1994-01-14 | 2002-11-29 | Xoma Technology Ltd | Metodos e materiais contra bacterias gram-positivas |
CA2181165C (en) * | 1994-01-14 | 2007-06-05 | Roger G. Ii Little | Anti-fungal methods and materials |
US5447913A (en) * | 1994-03-11 | 1995-09-05 | Xoma Corporation | Therapeutic uses of bactericidal/permeability-increasing protein dimer products |
US5646114A (en) * | 1994-07-11 | 1997-07-08 | Xoma Corporation | Anti-protozoan methods |
US6271203B1 (en) | 1994-07-07 | 2001-08-07 | Xoma Corporation | Anti-protozoan methods and materials |
WO1996008509A1 (en) * | 1994-09-15 | 1996-03-21 | Xoma Corporation | Anti-fungal peptides |
US5494896A (en) * | 1995-03-31 | 1996-02-27 | Xoma Corporation | Method of treating conditions associated with burn injuries |
CA2227292A1 (en) * | 1995-07-20 | 1997-02-06 | Xoma Corporation | Anti-fungal peptides |
ATE198050T1 (de) * | 1996-05-10 | 2000-12-15 | Xoma Technology Ltd | Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia |
US5741779A (en) * | 1996-05-10 | 1998-04-21 | Xoma Corporation | Antithrombotic materials and methods |
CN1155403C (zh) * | 1996-05-23 | 2004-06-30 | 爱克索马技术有限公司 | 杀细菌/通透性增加蛋白在制备用于治疗创伤出血病人的药物中的应用 |
AU3968597A (en) * | 1996-08-02 | 1998-02-25 | Children's Medical Center Corporation | Method of regulating the female reproductive system through angiogenesis inhibitors |
US5888973A (en) * | 1996-08-09 | 1999-03-30 | Xoma Corporation | Anti-chlamydial uses of BPI protein products |
US6482796B2 (en) | 1996-11-01 | 2002-11-19 | Xoma Corporation | Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients |
US6093573A (en) * | 1997-06-20 | 2000-07-25 | Xoma | Three-dimensional structure of bactericidal/permeability-increasing protein (BPI) |
WO1999039702A2 (en) * | 1997-10-31 | 1999-08-12 | Children's Medical Center Corporation | Method for regulating size and growth of vascularized normal tissue |
US6264596B1 (en) | 1997-11-03 | 2001-07-24 | Meadox Medicals, Inc. | In-situ radioactive medical device |
US6720311B2 (en) | 1997-12-18 | 2004-04-13 | David Tsai | Polypeptide for the treatment of cancer and a method for preparation thereof |
US7238662B2 (en) * | 1997-12-18 | 2007-07-03 | Ambryx Biotechnology, Inc. | Alpha 2HS glycoprotein for treatment of cancer and a method for preparation thereof |
US6737402B2 (en) | 1997-12-18 | 2004-05-18 | David Tsai | Method of preparing fetuin to induce apoptosis |
US5994298A (en) * | 1997-12-18 | 1999-11-30 | Tsai; David | Proteins for cancer cell specific induction of apoptosis and method for isolation thereof |
US6013631A (en) * | 1998-06-19 | 2000-01-11 | Xoma Corporation | Bactericidal/permeability-increasing protein (BPI) deletion analogs |
US6242219B1 (en) * | 1999-03-18 | 2001-06-05 | Xoma (Us) Llc | Methods for recombinant peptide production |
US6964948B2 (en) * | 1999-06-25 | 2005-11-15 | Xoma Technology Ltd. | Therapeutic peptide-based constructs derived from Domain II of bactericidal/permeability-increasing protein |
US6515104B1 (en) * | 1999-06-25 | 2003-02-04 | Xoma Technology Ltd. | Therapeutic peptide-based constructs derived from domain II of bactericidal/permeability-increasing protein |
EP1339424A2 (en) * | 2000-12-01 | 2003-09-03 | XOMA Technology Ltd. | Modulation of pericyte proliferation using bpi protein products or bpi inhibitors |
AU2003300588B2 (en) | 2002-03-29 | 2008-12-04 | Xoma Technology Ltd. | Methods vectors plasmids and methods for increasing expression of recombinant polypeptides |
EP1741440A1 (en) | 2005-07-08 | 2007-01-10 | Mellitus S.L. | Use of BPI protein for the treatment of disorders of the metabolism and cardiovascular disorders |
US8592393B2 (en) | 2007-11-02 | 2013-11-26 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
US9351992B2 (en) | 2007-11-02 | 2016-05-31 | Momenta Pharmaceuticals, Inc. | Non-anticoagulant polysaccharide compositions |
US8569262B2 (en) | 2007-11-02 | 2013-10-29 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
CA2795360A1 (en) | 2010-04-16 | 2011-10-20 | Momenta Pharmaceuticals, Inc. | Tissue targeting |
EP2582355A2 (en) | 2010-06-17 | 2013-04-24 | Momenta Pharmaceuticals, Inc. | Methods and compositions for promoting hair growth |
JP6040223B2 (ja) * | 2011-04-05 | 2016-12-07 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | 放射線緩和剤および放射線保護剤としてのbpiおよびその同類物 |
AU2014274377A1 (en) | 2013-05-28 | 2015-11-12 | Momenta Pharmaceuticals, Inc. | Pharmaceutical compositions |
GB201319620D0 (en) | 2013-11-06 | 2013-12-18 | Norwegian University Of Science And Technology | Immunosuppressive agents and their use in therapy |
GB201319621D0 (en) | 2013-11-06 | 2013-12-18 | Norwegian University Of Science And Technology | Antimicrobial agents and their use in therapy |
IT201700108102A1 (it) * | 2017-09-27 | 2019-03-27 | Univ Degli Studi Padova | Composizione di bactericidal/permeability increasing protein e acido ialuronico per il trattamento delle artropatie |
WO2019063320A1 (en) | 2017-09-27 | 2019-04-04 | Universita' Degli Studi Di Padova | COMPOSITION COMPRISING A BACTERICIDE / PERMEABILITY INCREASING PROTEIN AND HYALURONIC ACID FOR THE TREATMENT OF ARTHROPATHIES |
EP3566717A1 (en) | 2018-05-09 | 2019-11-13 | Universität Regensburg | Bactericidal/permeability increasing protein for use in a method of immunization, preferably as an adjuvant in a method of vaccination |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5262403A (en) * | 1986-03-10 | 1993-11-16 | Board Of Regents, The University Of Texas System | Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II |
ATE123291T1 (de) * | 1987-08-11 | 1995-06-15 | Univ New York | Biologisch aktive bakterientötende/durchlässigkeitserhöhende proteinfragmente. |
US5086164A (en) * | 1989-01-10 | 1992-02-04 | Repligen Corporation | Novel methods and compositions for treatment of angiogenic diseases |
US5089274A (en) * | 1989-02-14 | 1992-02-18 | Incyte Pharmaceuticals, Inc. | Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders |
US5171739A (en) * | 1989-02-14 | 1992-12-15 | Incyte Pharmaceuticals, Inc. | Treatment of endotoxin-associated shock and preventation thereof using a BPI protein |
US5112946A (en) * | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
US5221664A (en) * | 1990-04-23 | 1993-06-22 | Magainin Pharmaaceuticals Inc. | Composition and treatment with biologically active peptides and toxic cations |
EP0541716A1 (en) * | 1990-07-27 | 1993-05-19 | Repligen Corporation | Novel methods and compositions for treatment of angiogenic diseases |
WO1992009621A1 (en) * | 1990-12-03 | 1992-06-11 | New York University | Biologically active bactericidal/permeability-increasing protein fragments |
US5357041A (en) * | 1991-12-06 | 1994-10-18 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Heparin- and sulfatide-binding peptides from the type I repeats of human thrombospondin |
AU3592593A (en) * | 1992-01-16 | 1993-08-03 | Repligen Corporation | Novel methods and compositions for treatment of angiogenic diseases |
US5491130A (en) * | 1992-11-10 | 1996-02-13 | The United States Of America As Represented By The Department Of Health And Human Services | Peptide inhibitors of fibronectin and related collagen-binding proteins |
US5420019A (en) * | 1993-02-02 | 1995-05-30 | Xoma Corporation | Stable bactericidal/permeability-increasing protein muteins |
US5652332A (en) * | 1993-03-12 | 1997-07-29 | Xoma | Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof |
DK0690720T3 (da) * | 1993-03-12 | 2001-08-27 | Xoma Technology Ltd | Terapeutiske anvendelser af baktericide/permeabilitetsforøgende proteinprodukter |
-
1994
- 1994-03-11 DK DK94910854T patent/DK0690720T3/da active
- 1994-03-11 DE DE69427582T patent/DE69427582T2/de not_active Expired - Fee Related
- 1994-03-11 ES ES94910854T patent/ES2157981T3/es not_active Expired - Lifetime
- 1994-03-11 WO PCT/US1994/002401 patent/WO1994020128A1/en active IP Right Grant
- 1994-03-11 CN CN94191892A patent/CN1105574C/zh not_active Expired - Fee Related
- 1994-03-11 CA CA002157927A patent/CA2157927C/en not_active Expired - Fee Related
- 1994-03-11 EP EP94910854A patent/EP0690720B1/en not_active Expired - Lifetime
- 1994-03-11 CN CNA03104316XA patent/CN1478543A/zh active Pending
- 1994-03-11 EP EP00128250A patent/EP1129718A3/en not_active Withdrawn
- 1994-03-11 MX MX9401807A patent/MX9401807A/es not_active IP Right Cessation
- 1994-03-11 PT PT94910854T patent/PT690720E/pt unknown
- 1994-03-11 AU AU63605/94A patent/AU684503B2/en not_active Ceased
- 1994-03-11 JP JP6520214A patent/JPH08509703A/ja not_active Ceased
- 1994-03-11 NZ NZ263057A patent/NZ263057A/xx unknown
- 1994-03-11 AT AT94910854T patent/ATE202482T1/de not_active IP Right Cessation
-
1995
- 1995-03-31 US US08/415,158 patent/US5639727A/en not_active Expired - Lifetime
- 1995-05-05 US US08/435,855 patent/US5807818A/en not_active Expired - Fee Related
-
1998
- 1998-12-28 HK HK98115810A patent/HK1014497A1/xx not_active IP Right Cessation
-
2001
- 2001-08-27 US US09/942,021 patent/US20020090368A1/en not_active Abandoned
- 2001-09-20 GR GR20010401543T patent/GR3036686T3/el not_active IP Right Cessation
-
2005
- 2005-02-24 JP JP2005049791A patent/JP2005187480A/ja active Pending
- 2005-02-24 JP JP2005049792A patent/JP2005206606A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US5807818A (en) | 1998-09-15 |
DK0690720T3 (da) | 2001-08-27 |
DE69427582T2 (de) | 2001-10-04 |
AU6360594A (en) | 1994-09-26 |
NZ263057A (en) | 2000-12-22 |
CA2157927A1 (en) | 1994-09-15 |
CN1124455A (zh) | 1996-06-12 |
JPH08509703A (ja) | 1996-10-15 |
JP2005206606A (ja) | 2005-08-04 |
DE69427582D1 (de) | 2001-08-02 |
PT690720E (pt) | 2001-12-28 |
CN1105574C (zh) | 2003-04-16 |
ES2157981T3 (es) | 2001-09-01 |
WO1994020128A1 (en) | 1994-09-15 |
EP0690720A1 (en) | 1996-01-10 |
HK1014497A1 (en) | 1999-09-30 |
CA2157927C (en) | 1999-03-30 |
EP1129718A2 (en) | 2001-09-05 |
US5639727A (en) | 1997-06-17 |
US20020090368A1 (en) | 2002-07-11 |
EP1129718A3 (en) | 2002-05-22 |
AU684503B2 (en) | 1997-12-18 |
ATE202482T1 (de) | 2001-07-15 |
EP0690720B1 (en) | 2001-06-27 |
CN1478543A (zh) | 2004-03-03 |
JP2005187480A (ja) | 2005-07-14 |
GR3036686T3 (en) | 2001-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9401807A (es) | Usos terapeuticos de productos de proteina que incrementan lapermeabilidad/bactericidas. | |
ES2124203T1 (es) | Inhibidores de elastasa de neutrofilos humanos y catepsina g humana. | |
PT801564E (pt) | Utilizacao de nebivolol como agente anti-aterogernico | |
UA27911C2 (uk) | Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну | |
DE69920757D1 (de) | Immunsuppressive wirkungen von pteridinderivaten | |
ES2060310T3 (es) | Utilizacion de la n-miristoil-(s)-fenilalanina para la obtencion de medicamentos destinados al tratamiento de enfermedades que hacen intervenir la miristoilacion. | |
ES2119185T3 (es) | Tratamiento de enfermedades micobacterianas por administracion de productos de la proteina bactericida/que aumenta la permeabilidad. | |
NZ332721A (en) | Use of bactericidal/permeability increasing (BPI) protein sometimes in conjunction with a thrombolytic agent to treat thrombotic disorders | |
DE69133485D1 (de) | Verwendung von Staphylococcus Enterotoxin Homologe für Krebs-Therapie | |
DE69526216T2 (de) | Antifungaleverfahren und mitteln | |
NO973081D0 (no) | Fremgangmåte for behandling av kroniske progressive vaskulære sykdommer | |
IT8721115A0 (it) | Fitopreparato per la cura di affezioni cutanee. | |
ATE286122T1 (de) | Protein c derivate | |
ES1022449Y (es) | Aparato terapeutica para tratamiento de sintomas ocasionados por enfermedades. | |
NO913117D0 (no) | Fremgangsmaate for behandling av benoedeleggende sykdommer. | |
ATE246924T1 (de) | Neue therapeutische verwendung von nicergoline | |
DK113789A (da) | Thiosulfinsyrederivater, deres anvendelse til behandling af betaendelsessygdomme samt laegemiddel indeholdende disse stoffer | |
DK0455769T3 (da) | Anvendelse af 7-OH-1,2-benzopyron til fremstilling af et lægemiddel til behandling af magline tumore r hos mennesker | |
ES1022564Y (es) | Armonizador electromagnetico de las alteraciones fisiologicas del cuerpo humano. | |
YU40098A (sh) | Upotreba olanzapina za dobijanje leka | |
DE69201975T2 (de) | Pyrimido-benzothiazinderivate zur Behandlung von Entzündung, Allergie and kardiovaskulären Erkrankung. | |
NO912528D0 (no) | Behandling av sykdommer forbundet med jodmangel. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
MM | Annulment or lapse due to non-payment of fees |